Loading...
•
Oct 31, 2024
Engene Q4 2024 Earnings Report
enGene reported full year 2024 financial results and provided a business update.
Key Takeaways
enGene reported cash, cash equivalents and marketable securities of $297.9 million, which are expected to fund operations into 2027. The company also announced a BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.
BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.
All cohorts of the Phase 2 LEGEND study are now recruiting under the updated protocol.
Additional preliminary data from the pivotal cohort is anticipated in 2H 2025.
Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027.
Forward Guidance
enGene expects that its existing cash and cash equivalents will fund operating expenses, debt obligations and capital expenditures into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...